

Stefano Vella

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8304964/publications.pdf>

Version: 2024-02-01

253
papers

19,693
citations

23567

58
h-index

11308

136
g-index

258
all docs

258
docs citations

258
times ranked

15102
citing authors

#	ARTICLE	IF	CITATIONS
1	Isolation and preliminary characterization of a human ϕ phage display TM -derived antibody against neural adhesion molecule-1 antigen interfering with fibroblast growth factor receptor-1 binding. <i>Human Antibodies</i> , 2021, 29, 63-84.	1.5	2
2	Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 628-639.	3.0	7
3	Optimization of hepatitis C virus screening strategies by birth cohort in Italy. <i>Liver International</i> , 2020, 40, 1545-1555.	3.9	37
4	Multi-arm, multi-stage randomised controlled trials for evaluating therapeutic HIV cure interventions. <i>Lancet HIV</i> , 2019, 6, e334-e340.	4.7	5
5	Development of a novel human phage display-derived anti-LAG3 scFv antibody targeting CD8+ T lymphocyte exhaustion. <i>BMC Biotechnology</i> , 2019, 19, 67.	3.3	15
6	Intracellular human antibody fragments recognizing the VP35 protein of Zaire Ebola filovirus inhibit the protein activity. <i>BMC Biotechnology</i> , 2019, 19, 64.	3.3	18
7	Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data. <i>Pharmacoeconomics</i> , 2019, 37, 255-266.	3.3	12
8	Health and Climate Change: science calls for global action. <i>Annali Dell'Istituto Superiore Di Sanita</i> , 2019, 55, 323-329.	0.4	3
9	Soluble \langle sc \rangle CD \langle /sc \rangle 14 levels in plasma and breastmilk of Malawian \langle sc \rangle HIV \langle /sc \rangle + women: Lack of association with morbidity and mortality in their exposed infants. <i>American Journal of Reproductive Immunology</i> , 2018, 79, e12812.	1.2	4
10	The Manufacturers TM Perspective on World Health Organization Prequalification of In Vitro Diagnostics. <i>Clinical Infectious Diseases</i> , 2018, 66, 301-305.	5.8	10
11	Antibody response to hepatitis B vaccine in HIV ⁺ exposed infants in Malawi and correlation with HBV infection acquisition. <i>Journal of Medical Virology</i> , 2018, 90, 1172-1176.	5.0	5
12	Economic Evaluation of the Hepatitis C Virus Treatment Extension to Early-Stage Fibrosis Patients: Evidence from the PITER Real-World Cohort. <i>Value in Health</i> , 2018, 21, 783-791.	0.3	10
13	Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 383-403.	8.1	1,241
14	Mixed cryoglobulinaemia: An important but frequently unrecognized and underestimated \langle sc \rangle HCV \langle /sc \rangle -related condition in the real life practice. <i>Liver International</i> , 2018, 38, 183-183.	3.9	5
15	Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV. <i>Journal of Hepatology</i> , 2018, 68, 33-41.	3.7	19
16	Epidemiological and economic evaluations according to DAA treatment access: an interim evaluation based on PITER cohort data. <i>Journal of Virus Eradication</i> , 2018, 4, 25-26.	0.5	0
17	Patient-Reported Outcomes in First-Line Antiretroviral Therapy: Results From NEAT001/ANRS143 Trial Comparing Darunavir/Ritonavir in Combination With Tenofovir/Emtricitabine or Raltegravir. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 79, 519-526.	2.1	5
18	APOBEC3G/3A Expression in Human Immunodeficiency Virus Type 1-Infected Individuals Following Initiation of Antiretroviral Therapy Containing Cenicriviroc or Efavirenz. <i>Frontiers in Immunology</i> , 2018, 9, 1839.	4.8	11

#	ARTICLE	IF	CITATIONS
19	Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society's Lancet Commission. <i>Lancet</i> , The, 2018, 392, 312-358.	13.7	230
20	Forecasting Hepatitis C liver disease burden on real-life data. Does the <i>hidden iceberg</i> matter to reach the elimination goals?. <i>Liver International</i> , 2018, 38, 2190-2198.	3.9	33
21	Cytomegalovirus (CMV) DNA load in breast milk of human immunodeficiency virus-positive women and infant CMV infection acquisition are not reduced with long-term antiretroviral therapy. <i>Clinical Microbiology and Infection</i> , 2017, 23, 491-492.	6.0	3
22	Hepatitis E virus infection in HIV-infected pregnant women and their children in Malawi. <i>Infectious Diseases</i> , 2017, 49, 708-711.	2.8	8
23	Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 325-336.	8.1	208
24	Access to medicines: lessons from the HIV response. <i>Lancet HIV</i> , the, 2017, 4, e147-e149.	4.7	5
25	Predictors of attrition from care at 2 years in a prospective cohort of HIV-infected adults in Tigray, Ethiopia. <i>BMJ Global Health</i> , 2017, 2, e000325.	4.7	14
26	High CMV IgG antibody levels are associated to a lower CD4+ RESPONSE to antiretroviral therapy in HIV-infected women. <i>Journal of Clinical Virology</i> , 2017, 96, 17-19.	3.1	3
27	Modeling cost-effectiveness and health gains of a "universal" versus "prioritized" hepatitis C virus treatment policy in a real-life cohort. <i>Hepatology</i> , 2017, 66, 1814-1825.	7.3	25
28	CMV infection in a cohort of HIV-exposed infants born to mothers receiving antiretroviral therapy during pregnancy and breastfeeding. <i>Medical Microbiology and Immunology</i> , 2017, 206, 23-29.	4.8	7
29	Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study. <i>PLoS ONE</i> , 2017, 12, e0172159.	2.5	42
30	Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network. <i>PLoS ONE</i> , 2017, 12, e0185728.	2.5	37
31	Beyond viral suppression of HIV " the new quality of life frontier. <i>BMC Medicine</i> , 2016, 14, 94.	5.5	279
32	Validation of a self-reported HIV symptoms list: the ISS-HIV symptoms scale. <i>AIDS Research and Therapy</i> , 2016, 13, 18.	1.7	6
33	HCV-related mixed cryoglobulinemia: Data from PITER, a nationwide Italian HCV cohort study. <i>Digestive and Liver Disease</i> , 2016, 48, e6-e7.	0.9	1
34	Concentrations of tenofovir, lamivudine and efavirenz in mothers and children enrolled under the Option B-Plus approach in Malawi. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1027-1030.	3.0	32
35	Virological Response and Drug Resistance 1 and 2 Years Post-Partum in HIV-Infected Women Initiated on Life-Long Antiretroviral Therapy in Malawi. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 737-742.	1.1	9
36	Levels of bone markers in a population of infants exposed in utero and during breastfeeding to tenofovir within an Option B+ programme in Malawi. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3206-3211.	3.0	5

#	ARTICLE	IF	CITATIONS
37	From Durban to Durban: end of AIDS further than hoped. <i>Lancet HIV</i> ,the, 2016, 3, e403-e405.	4.7	4
38	Unite forces to validate biomarkers in the quest for lasting HIV remission. <i>Aids</i> , 2016, 30, 1859-1860.	2.2	2
39	Serum Phosphate and Creatinine Levels in the First Year of Life in Infants Born to HIV-Positive Mothers Receiving Tenofovir-Based Combination Regimens During Pregnancy and Prolonged Breastfeeding in an Option B+ Program in Malawi. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 73, e90-e91.	2.1	0
40	An update to the HIV-TRePS system: the development and evaluation of new global and local computational models to predict HIV treatment outcomes, with or without a genotype. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2928-2937.	3.0	7
41	Host and disease factors are associated with cognitive function in European <sc>HIV</sc>-infected adults prior to initiation of antiretroviral therapy. <i>HIV Medicine</i> , 2016, 17, 471-478.	2.2	7
42	Retention, transfer out and loss to follow-up two years after delivery in a cohort of HIV+ pregnant women in Malawi. <i>International Journal of STD and AIDS</i> , 2016, 27, 462-468.	1.1	8
43	Antibodies against pneumococcal capsular polysaccharide in Malawian HIV-positive mothers and their HIV-exposed uninfected children. <i>Infectious Diseases</i> , 2016, 48, 317-321.	2.8	6
44	First-line HIV therapy shall not fail. <i>Lancet HIV</i> ,the, 2016, 3, e108-e109.	4.7	0
45	A "systems medicine" approach to the study of non-alcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2016, 48, 333-342.	0.9	56
46	Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1056-1062.	3.0	22
47	Immunoterapia del cancro. <i>Global & Regional Health Technology Assessment</i> , 2016, 3, S1-S2.	0.1	0
48	Laboratory confirmation of clinically diagnosed malaria in a cohort of HIV-infected mothers and their children in Malawi. <i>Journal of Tropical Pediatrics</i> , 2015, 61, 222-225.	1.5	0
49	PITER: An ongoing nationwide study on the real-life impact of direct acting antiviral based treatment for chronic hepatitis C in Italy. <i>Digestive and Liver Disease</i> , 2015, 47, 741-743.	0.9	23
50	Drug resistance mutations 18 months after discontinuation of nevirapine-based ART for prevention of mother-to-child transmission of HIV in Malawi. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2881-2884.	3.0	4
51	Antisense versus proopiomelanocortin mRNA reduces vascular risk in a murine model of type-2 diabetes following stress exposure in early post-natal life. <i>Peptides</i> , 2015, 64, 34-39.	2.4	3
52	End of AIDS on the horizon, but innovation needed to end HIV. <i>Lancet HIV</i> ,the, 2015, 2, e74-e75.	4.7	11
53	Endogenous CCL2 neutralization restricts HIV-1 replication in primary human macrophages by inhibiting viral DNA accumulation. <i>Retrovirology</i> , 2015, 12, 4.	2.0	35
54	Addressing barriers to the end of AIDS by 2030. <i>Lancet HIV</i> ,the, 2015, 2, e360-e361.	4.7	8

#	ARTICLE	IF	CITATIONS
55	Anti-Streptococcus pneumoniae and rotavirus IgG levels in HIV-positive women do not correlate with maternal status and infant morbidity and mortality. <i>Journal of Medical Microbiology</i> , 2015, 64, 795-797.	1.8	2
56	Retention in Care of Adult HIV Patients Initiating Antiretroviral Therapy in Tigray, Ethiopia: A Prospective Observational Cohort Study. <i>PLoS ONE</i> , 2015, 10, e0136117.	2.5	28
57	Growth indices in breastfed infants pre and postnatally exposed to tenofovir compared with tenofovir-unexposed infants. <i>Aids</i> , 2015, 30, 1.	2.2	8
58	Maximizing the benefits of antiretroviral therapy for key affected populations. <i>Journal of the International AIDS Society</i> , 2014, 17, 19320.	3.0	15
59	Treatment as Prevention: unanswered questions and progress to date. <i>Journal of the International AIDS Society</i> , 2014, 17, 19521.	3.0	1
60	Rate, Predictors, and Consequences of Late Antenatal Booking in a National Cohort Study of Pregnant Women With HIV in Italy. <i>HIV Clinical Trials</i> , 2014, 15, 104-115.	2.0	11
61	Commentary. <i>Aids</i> , 2014, 28, S101-S104.	2.2	8
62	Viral Sequence Analysis of HIV-Positive Women and Their Infected Children: Insight on the Timing of Infection and on the Transmission Network. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 1010-1015.	1.1	4
63	Recovery of Interleukin-17 Production from Interleukin-15-Stimulated CD4+ Mononuclear Cells in HIV-1-Infected Patients with Sustained Viral Suppression. <i>Journal of Interferon and Cytokine Research</i> , 2014, 34, 35-40.	1.2	4
64	Using CD4 Percentage and Age to Optimize Pediatric Antiretroviral Therapy Initiation. <i>Pediatrics</i> , 2014, 134, e1104-e1116.	2.1	16
65	Weight Changes During and After 6 Months of Breastfeeding in HIV-Infected Mothers Receiving Antiretroviral Therapy in Malawi. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 1155-1157.	1.1	1
66	Ritonavir-boosted darunavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naïve adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. <i>Lancet, The</i> , 2014, 384, 1942-1951.	13.7	158
67	Viro-immunological response and emergence of resistance in HIV-infected women receiving combination antiretroviral regimens for the prevention of mother-to-child transmission in Malawi. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 749-752.	3.0	2
68	Atazanavir and lopinavir profile in pregnant women with HIV: tolerability, activity and pregnancy outcomes in an observational national study. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1377-1384.	3.0	13
69	A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe. <i>Infection</i> , 2014, 42, 757-762.	4.7	4
70	The impact of HBV or HCV infection in a cohort of HIV-infected pregnant women receiving a nevirapine-based antiretroviral regimen in Malawi. <i>BMC Infectious Diseases</i> , 2014, 14, 180.	2.9	12
71	Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: the D:A:D study. <i>BMC Nephrology</i> , 2014, 15, 51.	1.8	10
72	Deteriorating renal function and clinical outcomes in HIV-positive persons. <i>Aids</i> , 2014, 28, 727-737.	2.2	25

#	ARTICLE	IF	CITATIONS
73	Immuno-Virological Discordance and the Risk of Non-AIDS and AIDS Events in a Large Observational Cohort of HIV-Patients in Europe. PLoS ONE, 2014, 9, e87160.	2.5	35
74	Reconstitution of Intestinal CD4 and Th17 T Cells in Antiretroviral Therapy Suppressed HIV-Infected Subjects: Implication for Residual Immune Activation from the Results of a Clinical Trial. PLoS ONE, 2014, 9, e109791.	2.5	26
75	Clinical development of monoclonal antibody-based drugs in HIV and HCV diseases. BMC Medicine, 2013, 11, 4.	5.5	40
76	Raltegravir does not revert efflux activity of MDR1-P-glycoprotein in human MDR cells. BMC Pharmacology & Toxicology, 2013, 14, 47.	2.4	8
77	Targeting CCL2 inhibits viral DNA accumulation and induces APOBEC3A expression in HIV-1 infected primary human macrophages. Retrovirology, 2013, 10, .	2.0	0
78	HIV-1 coreceptor switch during 2Âyears of structured treatment interruptions. European Journal of Clinical Microbiology and Infectious Diseases, 2013, 32, 1565-1570.	2.9	4
79	Attention-Deficit/Hyperactivity Disorder Drugs and Growth: An Italian Prospective Observational Study. Journal of Child and Adolescent Psychopharmacology, 2013, 23, 440-447.	1.3	19
80	Adherence to Antiretroviral Therapy and Acceptability of Planned Treatment Interruptions in HIV-Infected Children. AIDS and Behavior, 2013, 17, 193-202.	2.7	6
81	Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet, The, 2013, 381, 2109-2117.	13.7	275
82	CD4 cell count and viral load-specific rates of AIDS, non-AIDS and deaths according to current antiretroviral use. Aids, 2013, 27, 907-918.	2.2	12
83	Associations between immune depression and cardiovascular events in HIV infection. Aids, 2013, 27, 2735-2748.	2.2	51
84	Association Between Antiretroviral Exposure and Renal Impairment Among HIV-Positive Persons With Normal Baseline Renal Function: the D:A:D Study. Journal of Infectious Diseases, 2013, 207, 1359-1369.	4.0	271
85	EZH2 Down-Regulation Exacerbates Lipid Accumulation and Inflammation in in Vitro and in Vivo NAFLD. International Journal of Molecular Sciences, 2013, 14, 24154-24168.	4.1	44
86	Optimization and simplification of antiretroviral therapy for adults and children. Current Opinion in HIV and AIDS, 2013, 8, 591-599.	3.8	12
87	Scaling up antiretroviral therapy in resource-limited settings. Current Opinion in HIV and AIDS, 2013, 8, 12-18.	3.8	38
88	Body Mass Index and Weight Gain in Pregnant Women With HIV: A National Study in Italy. Clinical Infectious Diseases, 2013, 56, 1190-1193.	5.8	0
89	Birth defects in a national cohort of pregnant women with <sc>HIV</sc> infection in <sc>Italy, 2001â€“2011. BJOG: an International Journal of Obstetrics and Gynaecology, 2013, 120, 1466-1476.	2.3	34
90	Preclinical validation of Aurora kinases-targeting drugs in osteosarcoma. British Journal of Cancer, 2013, 109, 2607-2618.	6.4	39

#	ARTICLE	IF	CITATIONS
91	Pregnancy Outcomes in HIV-Infected Women of Advanced Maternal Age. <i>HIV Clinical Trials</i> , 2013, 14, 110-119.	2.0	4
92	Outcomes after reinitiating antiretroviral therapy in children randomized to planned treatment interruptions. <i>Aids</i> , 2013, 27, 579-589.	2.2	24
93	Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: a cohort study. <i>BMC Infectious Diseases</i> , 2013, 13, 471.	2.9	68
94	Maternal Antiretroviral Therapy for the Prevention of Mother-To-Child Transmission of HIV in Malawi: Maternal and Infant Outcomes Two Years after Delivery. <i>PLoS ONE</i> , 2013, 8, e68950.	2.5	56
95	The Immunological and Virological Consequences of Planned Treatment Interruptions in Children with HIV Infection. <i>PLoS ONE</i> , 2013, 8, e76582.	2.5	29
96	The history of antiretroviral therapy and of its implementation in resource-limited areas of the world. <i>Aids</i> , 2012, 26, 1231-1241.	2.2	132
97	Enhanced brain performance in mice following postnatal stress. <i>Journal of Endocrinology</i> , 2012, 215, 413-424.	2.6	7
98	Antiretroviral Prophylaxis for Breastfeeding Transmission in Malawi: Drug Concentrations, Virological Efficacy and Safety. <i>Antiviral Therapy</i> , 2012, 17, 1511-1519.	1.0	37
99	The role of IL-15 in challenging Acquired Immunodeficiency Syndrome. <i>Cytokine</i> , 2012, 57, 54-60.	3.2	6
100	Cardiovascular Measures in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder Who Are New Users of Methylphenidate and Atomoxetine. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2012, 22, 423-431.	1.3	33
101	Emergence of lamivudine resistance hepatitis B virus mutations in pregnant women infected with HBV and HIV receiving antiretroviral prophylaxis for the prevention of mother-to-infant transmission in Malawi. <i>Journal of Medical Virology</i> , 2012, 84, 1553-1557.	5.0	13
102	Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011. <i>New Microbiologica</i> , 2012, 35, 113-59.	0.1	25
103	The Effect of SEX/Gender on Cardiovascular Pharmacology. <i>Current Pharmaceutical Design</i> , 2011, 17, 1095-1107.	1.9	33
104	HIV Persistence in the Gut Mucosa of HIV-Infected Subjects Undergoing Antiretroviral Therapy Correlates with Immune Activation and Increased Levels of LPS. <i>Current HIV Research</i> , 2011, 9, 148-153.	0.5	68
105	A GENS-based approach to cardiovascular pharmacology: impact on metabolism, pharmacokinetics and pharmacodynamics. <i>Therapeutic Delivery</i> , 2011, 2, 1437-1453.	2.2	28
106	A brief history of antiretroviral therapy of HIV infection: success and challenges. <i>Annali Dell'Istituto Superiore Di Sanita</i> , 2011, 47, 44-8.	0.4	85
107	Evaluation of HIV-1 integrase inhibitors on human primary macrophages using a luciferase-based single-cycle phenotypic assay. <i>Journal of Virological Methods</i> , 2010, 168, 272-276.	2.1	15
108	The Reverse Transcription Inhibitor Abacavir Shows Anticancer Activity in Prostate Cancer Cell Lines. <i>PLoS ONE</i> , 2010, 5, e14221.	2.5	48

#	ARTICLE	IF	CITATIONS
109	Nonnucleoside Reverse Transcriptase Inhibitor Concentrations During Treatment Interruptions and the Emergence of Resistance: A Substudy of the ISS-PART Trial. <i>AIDS Research and Human Retroviruses</i> , 2010, 26, 541-545.	1.1	7
110	Dynamic NAD(P)H post-synaptic autofluorescence signals for the assessment of mitochondrial function in a neurodegenerative disease: Monitoring the primary motor cortex of G93A mice, an amyotrophic lateral sclerosis model. <i>Mitochondrion</i> , 2010, 10, 108-114.	3.4	14
111	Correlation between HIV-1 viral load quantification in plasma, dried blood spots, and dried plasma spots using the Roche COBAS Taqman assay. <i>Journal of Clinical Virology</i> , 2010, 47, 4-7.	3.1	45
112	Sexual dimorphic evolution of metabolic programming in non-genetic non-alimentary mild metabolic syndrome model in mice depends on feed-back mechanisms integrity for pro-opiomelanocortin-derived endogenous substances. <i>Peptides</i> , 2010, 31, 1598-1605.	2.4	13
113	Post-natal stress-induced endocrine and metabolic alterations in mice at adulthood involve different pro-opiomelanocortin-derived peptides. <i>Peptides</i> , 2010, 31, 2123-2129.	2.4	22
114	Plasma Lipid Profile in Pregnant Women with HIV Receiving Nevirapine. <i>AIDS Patient Care and STDs</i> , 2009, 23, 147-152.	2.5	2
115	Antiretroviral Treatment in Pregnancy: A Six-Year Perspective on Recent Trends in Prescription Patterns, Viral Load Suppression, and Pregnancy Outcomes. <i>AIDS Patient Care and STDs</i> , 2009, 23, 513-520.	2.5	39
116	Comparison of HIV Type 1 Sequences from Plasma, Cell-Free Breast Milk, and Cell-Associated Breast Milk Viral Populations in Treated and Untreated Women in Mozambique. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 707-711.	1.1	9
117	Modifications of residual viraemia in human immunodeficiency virus-1-infected subjects undergoing repeated highly active antiretroviral therapy interruptions. <i>Journal of Medical Microbiology</i> , 2009, 58, 121-124.	1.8	1
118	The mutational archive in proviral DNA does not change during 24 months of continuous or intermittent highly active antiretroviral therapy. <i>HIV Medicine</i> , 2009, 10, 477-481.	2.2	11
119	Microbial translocation is associated with residual viral replication in HAART-treated HIV+ subjects with 50copies/ml HIV-1 RNA. <i>Journal of Clinical Virology</i> , 2009, 46, 367-370.	3.1	54
120	The Absence of HIV Mutations in Cerebrospinal Fluid and in Peripheral Blood Mononuclear Cells During a Regimen Containing Trizivir Plus Tenofovir. <i>Journal of Chemotherapy</i> , 2009, 21, 455-457.	1.5	1
121	Gender differences in the treatment of HIV infection. <i>Pharmacological Research</i> , 2008, 58, 173-182.	7.1	89
122	HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. <i>Aids</i> , 2008, 22, 2143-2153.	2.2	207
123	Single-nucleotide polymorphisms in human β -defensin-1 gene in Mozambican HIV-1-infected women and correlation with virologic parameters. <i>Aids</i> , 2008, 22, 1515-1517.	2.2	33
124	Factors Influencing Gestational Age-Adjusted Birthweight in a National Series of 600 Newborns from Mothers with HIV. <i>HIV Clinical Trials</i> , 2008, 9, 287-297.	2.0	11
125	Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?. <i>Aids</i> , 2008, 22, 2481-2492.	2.2	18
126	Tumor Necrosis Factor- α , Interleukin-10, and β -Defensins in Plasma and Breast Milk of HIV-Infected Highly Active Antiretroviral Therapy-Treated and Untreated Pregnant Women in Mozambique. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 47, 647-649.	2.1	5

#	ARTICLE	IF	CITATIONS
127	Modifications of HIV-1 DNA and Provirus-Infected Cells During 24 Months of Intermittent Highly Active Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 48, 68-71.	2.1	4
128	Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure?. <i>Aids</i> , 2008, 22, 2381-2390.	2.2	30
129	Simplified Maintenance Therapy with Abacavir/Lamivudine/Zidovudine plus Tenofovir After Sustained HIV Load Suppression: Four Years of Follow-up. <i>HIV Clinical Trials</i> , 2007, 8, 182-188.	2.0	6
130	Sex issues in HIV-1-infected persons during highly active antiretroviral therapy: a systematic review. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 60, 724-732.	3.0	124
131	Triple Antiretroviral Prophylaxis Administered During Pregnancy and After Delivery Significantly Reduces Breast Milk Viral Load. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 44, 286-291.	2.1	61
132	Resistance mutation patterns in plasma and breast milk of HIV-infected women receiving highly-active antiretroviral therapy for mother-to-child transmission prevention. <i>Aids</i> , 2007, 21, 2360-2362.	2.2	10
133	Redox Features of the Cell: A Gender Perspective. <i>Antioxidants and Redox Signaling</i> , 2007, 9, 1779-1802.	5.4	86
134	Antiretroviral Resistance Mutations in Untreated Pregnant Women with HIV Infection in Uganda and Rwanda. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 1449-1451.	1.1	8
135	Apoptosis-associated gene expression in HIV-infected patients in response to successful antiretroviral therapy. <i>Journal of Medical Virology</i> , 2007, 79, 111-117.	5.0	15
136	Seroprevalence of hepatitis B and C viruses among HIV-infected pregnant women in Uganda and Rwanda. <i>Journal of Medical Virology</i> , 2007, 79, 1797-1801.	5.0	65
137	Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death. <i>HIV Medicine</i> , 2007, 8, 96-104.	2.2	68
138	Determinants of Virologic and Immunologic Outcomes in Chronically HIV-Infected Subjects Undergoing Repeated Treatment Interruptions. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 46, 39-47.	2.1	36
139	Interleukin-15 enhances the secretion of IFN- γ and CC chemokines by natural killer cells from HIV viremic and aviremic patients. <i>Immunology Letters</i> , 2006, 103, 192-195.	2.5	19
140	Apoptotic Cell Signaling in Lymphocytes from HIV+ Patients during Successful Therapy. <i>Annals of the New York Academy of Sciences</i> , 2006, 1090, 130-137.	3.8	4
141	ISSQoL: A New Questionnaire for Evaluating the Quality of Life of People Living with HIV in the HAART Era*. <i>Quality of Life Research</i> , 2006, 15, 377-390.	3.1	27
142	Selection of Resistance Mutations in Children Receiving Prophylaxis With Lamivudine or Nevirapine for the Prevention of Postnatal Transmission of HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 42, 131-133.	2.1	8
143	Development of a Human Immunodeficiency Virus Vector-Based, Single-Cycle Assay for Evaluation of Anti-Integrase Compounds. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 3407-3417.	3.2	18
144	Follow-up on Metabolic Markers in Children Treated for Obstructive Sleep Apnea. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 174, 455-460.	5.6	67

#	ARTICLE	IF	CITATIONS
145	Absence of Unfavorable Effect of Atomoxetine on Growth in Pediatric Patients Is Still Not Demonstrated. <i>Pediatrics</i> , 2006, 117, 587-588.	2.1	2
146	Treatment for Adult HIV Infection. <i>JAMA - Journal of the American Medical Association</i> , 2006, 296, 827.	7.4	755
147	HIV-1 Subtypes and Response to Combination Antiretroviral Therapy in Europe. <i>Antiviral Therapy</i> , 2006, 11, 707-716.	1.0	52
148	Residual viraemia in subjects with chronic HIV infection and viral load < 50 copies/ml: the impact of highly active antiretroviral therapy. <i>Aids</i> , 2005, 19, 1843-1847.	2.2	47
149	Clinical outcome after 4 years follow-up of HIV-seropositive subjects with incomplete virologic or immunologic response to HAART. <i>Journal of Medical Virology</i> , 2005, 76, 153-160.	5.0	66
150	Association between Cellular Human Immunodeficiency Virus DNA Level and Immunological Parameters in Patients with Undetectable Plasma Viremia Level during Highly Active Antiretroviral Therapy. <i>Journal of Clinical Microbiology</i> , 2005, 43, 6183-6185.	3.9	21
151	Gender differences in clinical progression of HIV-1-infected individuals during long-term highly active antiretroviral therapy. <i>Aids</i> , 2005, 19, 577-583.	2.2	107
152	Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. <i>Aids</i> , 2005, 19, 593-601.	2.2	472
153	Mode of infant feeding and HIV infection in children in a program for prevention of mother-to-child transmission in Uganda. <i>Aids</i> , 2005, 19, 433-437.	2.2	43
154	Are Specific Antiretrovirals associated with an Increased Risk of Discontinuation due to Toxicities or Patient/Physician Choice in patients with Hepatitis C Virus Coinfection?. <i>Antiviral Therapy</i> , 2005, 10, 779-790.	1.0	22
155	Short Communication: Non-B HIV Type 1 Subtypes: Replicative Capacity and Response to Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2004, 20, 816-818.	1.1	13
156	Inverse correlation between CD8+ lymphocyte apoptosis and CD4+ cell counts during potent antiretroviral therapy in HIV patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2004, 53, 494-500.	3.0	9
157	Predictors of Immunological Failure after Initial Response to Highly Active Antiretroviral Therapy in HIV-1-Infected Adults: A EuroSIDA Study. <i>Journal of Infectious Diseases</i> , 2004, 190, 148-155.	4.0	58
158	Interleukin-15 production by monocyte-derived dendritic cells and T cell proliferation in HIV-infected patients with discordant response to highly active antiretroviral therapy. <i>Clinical and Experimental Immunology</i> , 2004, 135, 280-285.	2.6	9
159	Risk factors and occurrence of rash in HIV-positive patients not receiving nonnucleoside reverse transcriptase inhibitor: data from a randomized study evaluating use of protease inhibitors in nucleoside-experienced patients with very low CD4 levels (<50 cells/mm ³). <i>HIV Medicine</i> , 2004, 5, 1-10.	2.2	17
160	Factors Influencing Medication Adherence Beliefs and Self-Efficacy in Persons Naive to Antiretroviral Therapy: A Multicenter, Cross-Sectional Study. <i>AIDS and Behavior</i> , 2004, 8, 141-150.	2.7	161
161	Changing incidence of central nervous system diseases in the EuroSIDA cohort. <i>Annals of Neurology</i> , 2004, 55, 320-328.	5.3	273
162	Treatment for Adult HIV Infection. <i>JAMA - Journal of the American Medical Association</i> , 2004, 292, 251.	7.4	482

#	ARTICLE	IF	CITATIONS
163	Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. <i>Lancet, The</i> , 2004, 364, 51-62.	13.7	303
164	Causes of death in HIV infection. <i>Aids</i> , 2004, 18, 2333-2337.	2.2	34
165	Italian Attention-Deficit/Hyperactivity Disorder Registry. <i>Pediatrics</i> , 2004, 114, 514-514.	2.1	21
166	HIV clinical research in developing countries: challenges and priorities. <i>Journal of HIV Therapy</i> , 2004, 9, 49.	0.6	0
167	CD4+Lymphocyte Increases in HIV Patients during Potent Antiretroviral Therapy Are Dependent on Inhibition of CD8+Cell Apoptosis. <i>Annals of the New York Academy of Sciences</i> , 2003, 1010, 560-564.	3.8	3
168	Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy. <i>Journal of Medical Virology</i> , 2003, 69, 1-6.	5.0	59
169	Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study. <i>HIV Medicine</i> , 2003, 4, 255-262.	2.2	181
170	Comparison of Four-Drug Regimens and Pairs of Sequential Three-Drug Regimens as Initial Therapy for HIV-1 Infection. <i>New England Journal of Medicine</i> , 2003, 349, 2304-2315.	27.0	218
171	Drug-Associated Resistance Mutations in Plasma and Peripheral Blood Mononuclear Cells of Human Immunodeficiency Virus Type 1-Infected Patients for Whom Highly Active Antiretroviral Therapy Is Failing. <i>Journal of Clinical Microbiology</i> , 2003, 41, 1760-1762.	3.9	28
172	High Prevalence of M184 Mutation among Patients with Viroimmunologic Discordant Responses to Highly Active Antiretroviral Therapy and Outcomes after Change of Therapy Guided by Genotypic Analysis. <i>Journal of Clinical Microbiology</i> , 2003, 41, 3007-3012.	3.9	14
173	Mitochondrial Membrane Hyperpolarization Hijacks Activated T Lymphocytes Toward the Apoptotic-Prone Phenotype: Homeostatic Mechanisms of HIV Protease Inhibitors. <i>Journal of Immunology</i> , 2003, 170, 6006-6015.	0.8	74
174	A Randomized Trial of 2 Different 4â€Drug Antiretroviral Regimens versus a 3â€Drug Regimen, in Advanced Human Immunodeficiency Virus Disease. <i>Journal of Infectious Diseases</i> , 2003, 188, 625-634.	4.0	77
175	Comparison of Sequential Three-Drug Regimens as Initial Therapy for HIV-1 Infection. <i>New England Journal of Medicine</i> , 2003, 349, 2293-2303.	27.0	340
176	Combination Antiretroviral Therapy and the Risk of Myocardial Infarction. <i>New England Journal of Medicine</i> , 2003, 349, 1993-2003.	27.0	1,560
177	Future Treatment Perspectives. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003, 34, S95-S100.	2.1	2
178	Inhibition of vaginal transmission of HIV-1 in hu-SCID mice by the non-nucleoside reverse transcriptase inhibitor TMC120 in a gel formulation. <i>Aids</i> , 2003, 17, 1597-1604.	2.2	110
179	Selection of resistance mutations in pregnant women receiving zidovudine and lamivudine to prevent HIV perinatal transmission. <i>Aids</i> , 2003, 17, 1570-1572.	2.2	18
180	Beyond lipodystrophy: will toxicity issues ever outweigh the benefits of HAART?. <i>Journal of HIV Therapy</i> , 2003, 8, 27-8.	0.6	0

#	ARTICLE	IF	CITATIONS
181	Changes in Viral Load in People with Virological Failure who Remain on the Same Haart Regimen. <i>Antiviral Therapy</i> , 2003, 8, 127-136.	1.0	24
182	Association of Virus Load, CD4 Cell Count, and Treatment with Clinical Progression in Human Immunodeficiency Virus-Infected Patients with Very Low CD4 Cell Counts. <i>Journal of Infectious Diseases</i> , 2002, 186, 189-197.	4.0	52
183	Antiretroviral Treatment for Adult HIV Infection in 2002. <i>JAMA - Journal of the American Medical Association</i> , 2002, 288, 222.	7.4	632
184	In Vitro and In Vivo Modulation of MDR1/P-Glycoprotein in HIV-Infected Patients Administered Highly Active Antiretroviral Therapy and Liposomal Doxorubicin. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2002, 30, 369-378.	2.1	20
185	Discordant response to antiretroviral therapy. <i>Aids</i> , 2002, 16, 1877-1885.	2.2	18
186	Time to act: global apathy towards HIV/AIDS is a crime against humanity. <i>Lancet, The</i> , 2002, 360, 1710-1711.	13.7	39
187	HIV-related morbidity and mortality in patients starting protease inhibitors in very advanced HIV disease (CD4 count of < 50 cells/uL): an analysis of 338 clinical events from a randomized clinical trial*. <i>HIV Medicine</i> , 2002, 3, 75-84.	2.2	22
188	Antiretroviral drug resistance and HIV/AIDS in the developing world. <i>Journal of HIV Therapy</i> , 2002, 7, 53-5.	0.6	2
189	Markers of cell death-activation in lymphocytes of vertically HIV-infected children naive to highly active antiretroviral therapy: The role of age. <i>Journal of Allergy and Clinical Immunology</i> , 2001, 108, 439-445.	2.9	14
190	Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine. <i>Aids</i> , 2001, 15, 1269-1274.	2.2	52
191	hu-SCID: A model for the evaluation of vaginal microbicides. <i>Aids</i> , 2001, 15, S19.	2.2	0
192	Expression of P-170 glycoprotein sensitizes lymphoblastoid CEM cells to mitochondria-mediated apoptosis. <i>Biochemical Journal</i> , 2001, 355, 587-595.	3.7	26
193	Vaginal transmission of HIV-1 in hu-SCID mice: a new model for the evaluation of vaginal microbicides. <i>Aids</i> , 2001, 15, 2231-2238.	2.2	41
194	HIV-Protease Inhibitors Contribute to P-Glycoprotein Efflux Function Defect in Peripheral Blood Lymphocytes From HIV-Positive Patients Receiving HAART. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2001, 27, 321-330.	2.1	25
195	Modification of cell perfusion for extended study of hormone release in the rat pituitary. <i>Cytotechnology</i> , 2001, 23, 197-204.	0.7	7
196	Mission now possible for AIDS fund. <i>Nature</i> , 2001, 412, 271-272.	27.8	9
197	Success hinges on support for treatment. <i>Nature</i> , 2001, 412, 272-272.	27.8	2
198	Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. <i>Aids</i> , 2001, 15, 309-320.	2.2	169

#	ARTICLE	IF	CITATIONS
199	High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. <i>Aids</i> , 2001, 15, 1089-1095.	2.2	190
200	Access to HIV/AIDS Care and Treatment in the South of the World. <i>Aids</i> , 2001, 15, IAS1-IAS3.	2.2	1
201	Changes in apoptosis after interruption of potent antiretroviral therapy in patients with maximal HIV-1-RNA suppression. <i>Aids</i> , 2001, 15, 1178-1181.	2.2	3
202	Early immune reconstitution after potent antiretroviral therapy in HIV-infected children correlates with the increase in thymus volume. <i>Aids</i> , 2000, 14, 251-261.	2.2	86
203	Deregulation of the CD95/CD95L system in lymphocytes from patients with primary acute HIV infection. <i>Aids</i> , 2000, 14, 345-355.	2.2	30
204	Quality of life outcomes of combination zidovudine+didanosine+nevirapine and zidovudine+didanosine for antiretroviral-naïve advanced HIV-infected patients. <i>Aids</i> , 2000, 14, 2567-2574.	2.2	24
205	Spontaneous and anti-Fas-induced apoptosis in lymphocytes from HIV-infected patients undergoing highly active anti-retroviral therapy. <i>Aids</i> , 2000, 14, 939-949.	2.2	23
206	Plasma HIV-1 copy number and in vitro infectivity of plasma prior to and during combination antiretroviral treatment. <i>Antiviral Research</i> , 2000, 47, 189-198.	4.1	13
207	Antiretroviral therapy: state of the HAART. <i>Antiviral Research</i> , 2000, 45, 1-7.	4.1	71
208	Indinavir Pharmacokinetics and Pharmacodynamics in Children with Human Immunodeficiency Virus Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 752-755.	3.2	41
209	Prevalence and Characteristics of Multinucleoside-Resistant Human Immunodeficiency Virus Type 1 among European Patients Receiving Combinations of Nucleoside Analogues. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 2109-2117.	3.2	101
210	Hospitalizations and Costs of Treatment for Protease Inhibitor-Based Regimens in Patients with Very Advanced HIV-Infection (CD4 < 50/mm ³). <i>HIV Clinical Trials</i> , 2000, 1, 9-16.	2.0	12
211	HIV eradication revisited. <i>Expert Opinion on Investigational Drugs</i> , 2000, 9, 193-197.	4.1	2
212	Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection. <i>JAMA - Journal of the American Medical Association</i> , 2000, 283, 2417.	7.4	647
213	Antiretroviral Therapy in Adults. <i>JAMA - Journal of the American Medical Association</i> , 2000, 283, 381.	7.4	951
214	SPECT during sleepwalking. <i>Lancet</i> , The, 2000, 356, 484-485.	13.7	300
215	A Randomized Trial Comparing the Introduction of Ritonavir or Indinavir in 1251 Nucleoside-Experienced Patients with Advanced HIV Infection. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 1809-1820.	1.1	9
216	Randomised, Multicentre Phase III Study of Saquinavir plus Zidovudine plus Zalcitabine in Previously Untreated or Minimally Pretreated HIV-Infected Patients. <i>Clinical Drug Investigation</i> , 2000, 20, 295-307.	2.2	12

#	ARTICLE	IF	CITATIONS
217	Thymus volume correlates with the progression of vertical HIV infection. <i>Aids</i> , 1999, 13, F29-F34.	2.2	49
218	Circulating Antineutrophil Autoantibodies in a Child with Isolated Central Nervous System Vasculitis. <i>Neuropediatrics</i> , 1999, 30, 268-269.	0.6	8
219	Longitudinal Human Immunodeficiency Virus Type 1 Load in the Italian Seroconversion Study: Correlates and Temporal Trends of Virus Load. <i>Journal of Infectious Diseases</i> , 1999, 180, 1018-1024.	4.0	66
220	Clinical and immuno-virologic characterization of the efficacy of stavudine, lamivudine, and indinavir in human immunodeficiency virus infection. <i>Journal of Pediatrics</i> , 1999, 135, 675-682.	1.8	33
221	The relationship between ritonavir plasma levels and side-effects: implications for therapeutic drug monitoring. <i>Aids</i> , 1999, 13, 2083-2089.	2.2	156
222	AGITATED SLEEPWALKING WITH FLUOROQUINOLONE THERAPY. <i>Pediatric Infectious Disease Journal</i> , 1999, 18, 484-485.	2.0	16
223	Frequency and determinants of use of antiretroviral and prophylactic therapies against <i>Pneumocystis carinii</i> Pneumonia (PCP) before AIDS diagnosis in Italy. <i>European Journal of Epidemiology</i> , 1998, 14, 41-47.	5.7	7
224	Summary of the international consensus symposium on management of HIV, CMV and hepatitis virus infections. <i>Antiviral Research</i> , 1998, 37, 1-16.	4.1	29
225	Saquinavir delays the emergence of zidovudine resistance in HIV-1 seropositive patients treated with combination therapy. , 1998, 56, 332-336.		1
226	HIV treatment - a rational approach to the use of antiretroviral agents. <i>Haemophilia</i> , 1998, 4, 616-618.	2.1	0
227	British HIV Association guidelines. <i>Lancet, The</i> , 1998, 352, 1226-1227.	13.7	1
228	Changing patterns of mortality across Europe in patients infected with HIV-1. <i>Lancet, The</i> , 1998, 352, 1725-1730.	13.7	1,182
229	Saquinavir. <i>Clinical Pharmacokinetics</i> , 1998, 34, 189-201.	3.5	66
230	A Randomized, Double-blind Trial Comparing Combinations of Nevirapine, Didanosine, and Zidovudine for HIV-Infected Patients. <i>JAMA - Journal of the American Medical Association</i> , 1998, 279, 930.	7.4	694
231	Antiretroviral Drug Resistance Testing in Adults With HIV Infection. <i>JAMA - Journal of the American Medical Association</i> , 1998, 279, 1984.	7.4	528
232	Antiretroviral Therapy for HIV Infection in 1998. <i>JAMA - Journal of the American Medical Association</i> , 1998, 280, 78.	7.4	764
233	Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. <i>Aids</i> , 1998, 12, 1619-1624.	2.2	237
234	Inductionâ€“maintenance antiretroviral therapy. <i>Aids</i> , 1998, 12, F41-F44.	2.2	70

#	ARTICLE	IF	CITATIONS
235	Estimates of the virological benefit of antiretroviral therapy are both assay- and analysis-dependent. <i>Aids</i> , 1998, 12, 2185-2192.	2.2	6
236	Phase II controlled trial of post-exposure immunization with recombinant gp160 versus antiretroviral therapy in asymptomatic HIV-1-infected adults. <i>Aids</i> , 1998, 12, 473-480.	2.2	35
237	A Randomized Controlled Study for the Evaluation of the Activity of a Triple Combination of Zidovudine, Thymosin- α 1 and Interferon- α in HIV-Infected Individuals with CD4 Counts between 200 and 500 cells/mm ³ . <i>Antiviral Therapy</i> , 1998, 3, 103-111.	1.0	7
238	High-Dose Nevirapine in Previously Untreated Human Immunodeficiency Virus Type 1-Infected Persons Does Not Result in Sustained Suppression of Viral Replication. <i>Journal of Infectious Diseases</i> , 1997, 175, 966-970.	4.0	88
239	Survival of AIDS patients according to type of AIDS-defining event. The AIDS in Europe Study Group. <i>International Journal of Epidemiology</i> , 1997, 26, 400-407.	1.9	69
240	HIV phenotype switching during antiretroviral therapy. <i>Aids</i> , 1997, 11, 1211-1217.	2.2	19
241	Correlation between Changes in Plasma HIV RNA Levels and in Plasma Infectivity in Response to Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 1997, 13, 555-561.	1.1	18
242	Regional Differences in Use of Antiretroviral Agents and Primary Prophylaxis in 3122 European HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1997, 16, 153-160.	0.3	58
243	AIDS dementia complex in the Italian National AIDS Registry: temporal trends (1987-93) and differential incidence according to mode of transmission of HIV-1 infection. <i>Journal of the Neurological Sciences</i> , 1996, 144, 107-113.	0.6	38
244	A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patients. <i>Aids</i> , 1996, 10, 635-642.	2.2	73
245	Epidemiology of AIDS-related Kaposi's sarcoma in Europe over 10 years. <i>Aids</i> , 1996, 10, 911-918.	2.2	48
246	Saquinavir/zidovudine combination in patients with advanced HIV infection and no prior antiretroviral therapy: CD4 + lymphocyte/plasma RNA changes, and emergence of HIV strains with reduced phenotypic sensitivity. <i>Antiviral Research</i> , 1996, 29, 91-93.	4.1	28
247	Reduced sensitivity to saquinavir: an update on genotyping from phase I/II trials. <i>Antiviral Research</i> , 1996, 29, 95-97.	4.1	34
248	Tuberculosis among European patients with the acquired immune deficiency syndrome. <i>Tubercle and Lung Disease</i> , 1996, 77, 322-328.	2.1	25
249	Effect of sex, age and transmission category on the progression to AIDS and survival of zidovudine-treated symptomatic patients. <i>Aids</i> , 1995, 9, 51-56.	2.2	46
250	Plasma Viremia Titration and RNA Quantitation in ICD-p24 Negative HIV Type-1-Infected Patients. <i>AIDS Research and Human Retroviruses</i> , 1995, 11, 1203-1207.	1.1	10
251	Update on a proteinase inhibitor. <i>Aids</i> , 1994, 8, S25-S30.	2.2	46
252	The Effects of AZT and DDI on Pre- and Postimplantation Mammalian Embryos: An In Vivo and In Vitro Study. <i>AIDS Research and Human Retroviruses</i> , 1992, 8, 639-649.	1.1	20

#	ARTICLE	IF	CITATIONS
253	Antibody reactive in antibody-dependent cell-mediated cytotoxicity following influenza virus vaccination. <i>Journal of Medical Virology</i> , 1980, 6, 203-211.	5.0	26